A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (Soft Tissue Sarcoma)
Sponsor: SpringWorks Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS5686
U.S. Govt. ID: NCT03785964
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the safety and effectiveness of the study drug nirogacestat for the treatment of desmoid tumors/aggressive fibromatosis (DT/AF). One group will receive the study medication, the other group will receive a placebo. After the initial phase of the study, participants may elect to participate in another phase of the study in which all participants receive the nirogacestat. Nirogacestat blocks certain signals in the cell that may be responsible for the growth of desmoid tumors (soft tissue sarcoma).
This study is closed
Gary Schwartz, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with desmoid tumors/aggressive fibromatosis? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator